CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) traded up 12.9% during trading on Monday . The stock traded as high as $9.90 and last traded at $9.71, with a volume of 77,316 shares trading hands. The stock had previously closed at $8.60.

Separately, Zacks Investment Research raised CoLucid Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 24th.

The company’s market capitalization is $145.52 million. The company has a 50 day moving average price of $8.78 and a 200 day moving average price of $7.14.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last released its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.22. Equities analysts anticipate that CoLucid Pharmaceuticals Inc. will post ($4.01) EPS for the current year.

In other CoLucid Pharmaceuticals news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of the company’s stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $8.45, for a total transaction of $1,293,086.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.